JAMA Oncology Publishes Results Of Phase III Study For Prestige BioPharma's HERCEPTIN Biosimilar, HD201 - Food, Drugs, Healthcare, Life Sciences

On March 14, 2022, Prestige BioPharma Ltd., a Singapore-based biopharmaceutical company, announced positive safety and efficacy results in a Phase III study ("TROIKA") for HD201

Related Keywords

Singapore , ,Prestige Biopharma Ltd ,Mondaq ,Jama Oncology Publishes Results Of Phase Iii Study For Prestige Biopharmas Herceptin Biosimilar ,D201 ,Food ,Drugs ,Healthcare ,Life Sciences ,Food And Drugs Law ,Iotechnology Amp Nanotechnology ,